Earle C C, Maroun J A
Center for Outcomes and Policy Research, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA.
Eur J Cancer. 1999 Jul;35(7):1059-64. doi: 10.1016/s0959-8049(99)00076-3.
The aim of this study was to assess whether adjuvant chemotherapy after curative resection of gastric cancer increases survival rates.
MEDLINE (1966-1999), CancerLit (1983-1999), bibliographies, personal reprint files, and review articles were searched for relevant articles. Studies had to be randomised controlled trials of adjuvant chemotherapy versus observation following curative resection of stomach cancer that took place in non-Asian countries. Two reviewers independently evaluated the trials for eligibility, quality assessment and data abstraction, 13 trials met the eligibility criteria. The odds ratio for death in the treated group was 0.80 (95% confidence interval (CI) 0.66-0.97), corresponding to a relative risk of 0.94 (95% CI 0.89-1.00). Subgroup analyses showed a trend towards a larger magnitude of the effect when analysis was restricted to trials in which at least 2/3 of patients had node-positive disease. Our results suggest that adjuvant chemotherapy may produce a small survival benefit of borderline statistical significance in patients with curatively resected gastric carcinoma. Continued trials to find and confirm an effective adjuvant strategy are warranted.
本研究旨在评估胃癌根治性切除术后辅助化疗是否能提高生存率。
检索MEDLINE(1966 - 1999年)、CancerLit(1983 - 1999年)、参考文献目录、个人重印文献档案及综述文章以查找相关文章。研究必须是在非亚洲国家进行的胃癌根治性切除术后辅助化疗与观察对比的随机对照试验。两名审阅者独立评估试验的合格性、质量评估及数据提取,13项试验符合合格标准。治疗组的死亡比值比为0.80(95%置信区间(CI)0.66 - 0.97),相对危险度为0.94(95% CI 0.89 - 1.00)。亚组分析显示,当分析仅限于至少2/3患者有淋巴结阳性疾病的试验时,效应量有增大趋势。我们的结果表明,辅助化疗可能对根治性切除的胃癌患者产生微小的生存获益,且具有临界统计学意义。有必要继续进行试验以寻找并确认有效的辅助治疗策略。